2-Fluoroamphetamine (2-FA) is a synthetic stimulant of the substituted amphetamine class -- a primary amine with a fluorine atom at the ortho (2-) position of the phenyl ring. It is the desmethyl analog of 2-FMA: structurally, 2-FA is to amphetamine as 2-FMA is to methamphetamine. That single missing N-methyl group changes the pharmacological character significantly -- 2-FA is shorter-acting (3-6 hours versus 2-FMA's 6-10+), produces a more stimulating peak, and carries more peripheral side effects along the way. Community users consistently describe it as "the most amphetamine-like" of the fluoroamphetamine series, chosen more for its familiar stimulant character than for any unique property.
The mechanism of action is inferred rather than proven. No published in vitro binding affinity data exists specifically for 2-FA -- a gap the scientific literature has only recently begun to address. Based on its structural relationship to amphetamine and community effect reports, 2-FA almost certainly functions as a dopamine/norepinephrine releasing agent with minimal serotonergic activity. This stands in stark contrast to its positional isomer 4-FA (para-fluoroamphetamine), which has significant serotonin release, empathogenic effects, and -- critically -- has caused deaths from cerebral hemorrhage and cardiovascular collapse in the Netherlands. 2-FA does not share this serotonergic danger. The distinction matters: if your "2-FA" is actually 4-FA (and DrugsData has confirmed this mislabeling occurs), you are taking a fundamentally more dangerous substance.
Anchondo, Shetty & Gatch (2025) published the first in vivo behavioral data on 2-FA in mice and rats. The results were surprising: 2-FA produced peak locomotor effects of 5905-7758 counts, matching methamphetamine -- while its N-methylated cousin 2-FMA managed only 2200-3980 counts. The primary amine is paradoxically the more potent peak stimulant in animal models. In drug discrimination assays, all fluorinated amphetamine analogs fully substituted for methamphetamine (ED50 0.32-0.71 mg/kg), suggesting comparable abuse potential across the series.
Community use centers on functional stimulation and ADHD self-medication, though 2-FA is the less popular choice in its own family -- a study published in Brain Sciences found that 19.2% of novel psychoactive substance users chose it for ADHD management versus 46% for 2-FMA. The ceiling effect is well-documented and shapes the entire use profile: beyond roughly 60 mg, increasing the dose primarily escalates side effects (heart rate, jitteriness, sweating) without proportional gains in focus or euphoria. One Bluelight user captured the redosing dynamic perfectly: "not exactly because the reward was so big but it seemed to be right around the corner but never really came." No standalone fatality has been attributed to 2-FA, but its safety profile remains entirely uncharacterized by formal clinical study.
Safety at a Glance
High Risk- Start Low, Go Oral
- The Ceiling Dose
- Toxicity: Cardiovascular Risks All sympathomimetic stimulants elevate heart rate and blood pressure, and 2-FA is no exception. ...
- Dangerous with: Atropa belladonna, Datura, Diphenhydramine, Harmala alkaloid, 25x-NBOMe, 2C-T-x, DOx (+2 more)
- Overdose risk: Stimulant overdose is a medical emergency . 2-FA's shorter duration compared to compounds like 2-...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 2 hrs – 4 hrsHow It Feels
The onset of oral 2-FA takes its time -- thirty to forty-five minutes of gradual buildup before the effects declare themselves. The first sign is usually a quiet sharpening of attention, a sense that the mental static has been turned down. Tasks come into focus. There is an emerging feeling of purposeful alertness that, at functional doses of 10-20 mg, feels remarkably organic -- less like a drug kicking in and more like a particularly good morning.
Vaya, writing on Erowid (report ID 101915, titled "So Fresh and So Clean"), described the quality precisely: "clean, clear, bright, crisp, lucid and consistent." That phrase captures the 2-FA experience at its best. The focus is sharp but not forced. Appetite recedes into the background -- you can eat, but the impulse evaporates. Heart rate rises modestly; Vaya documented an increase from 72 to 80 bpm, which is typical of functional doses. There is no jaw clenching, no nystagmus, no serotonergic warmth. Just clean catecholaminergic drive.
At moderate doses (20-40 mg), the character shifts toward traditional amphetamine territory. Mild euphoria emerges -- a cognitive brightness, an optimistic hum. Energy increases noticeably; physical activity feels appealing rather than obligatory. One Bluelight user described the experience as having "felt very similar to adderall mixed with vyvanse but had more euphoria on onset...and a much calmer focused feeling." Another Erowid report titled it simply: "Smoother than Adderall." The comparison to pharmaceutical amphetamine is consistent across community reports -- 2-FA sits in the same pharmacological neighborhood but with a softer edge.
The ceiling effect defines the upper dose range. Beyond roughly 60 mg, the desirable effects plateau while side effects -- jitteriness, excessive sweating, elevated heart rate, anxiety -- continue climbing. The experience of pushing higher doses was captured memorably by a Bluelight user who found the redosing urge came "not exactly because the reward was so big but it seemed to be right around the corner but never really came." This is the pharmacological ceiling in subjective terms: diminishing euphoric returns with increasing sympathomimetic cost.
Duration is where 2-FA distinguishes itself from its longer-acting cousin 2-FMA. The total experience runs 3-6 hours orally, with most users reporting 4-5 hours of meaningful effects. The offset is gradual and forgiving -- Vaya described it as "a gentle and consistent downward slope." There is no harsh crash, no abrupt rebound depression. Fatigue settles in naturally as the drug clears, and sleep is generally possible within a few hours of the last dose (assuming afternoon timing). Compared to 2-FMA's 6-10+ hour duration or conventional amphetamine's 6-8 hours, 2-FA offers a shorter commitment -- which is either a feature (flexibility, less sleep disruption) or a liability (more temptation to redose). Drugs-Forum user darkbreed summarized the experience arc concisely: clean stimulation, alertness, focus, creativity, improved concentration -- "good for anything needed to be done that requires concentration" -- with a smooth, unremarkable return to baseline.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(6)
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Cognitive & Perceptual Effects
Cognitive(6)
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
Pharmacology
Mechanism of Action: Inferred, Not Proven
The single most important caveat about 2-FA pharmacology is that no published in vitro binding affinity or transporter release data exists for this specific compound. As Anchondo et al. (2025) stated plainly: "while there is substantial study on 4-position-substituted compounds and limited data on 3-position-substituted compounds, there is little to no information on 2-position-substituted compounds."
What we know is structural inference. 2-FA is a primary amine bearing a fluorine at the ortho position -- structurally close enough to amphetamine that it almost certainly functions as a substrate-type monoamine releasing agent, entering presynaptic terminals via the dopamine transporter (DAT) and norepinephrine transporter (NET) and triggering reverse transport of stored catecholamines. Community reports consistently describe an effect profile dominated by noradrenergic/dopaminergic stimulation with negligible serotonergic character, supporting this inference.
Positional Isomer Data: What the Neighbors Tell Us
The best available pharmacological data comes from 2-FA's positional isomers. Baumann et al. characterized 3-FA (PAL-353) in vitro: DA release EC50 24.2 nM, NE release EC50 16.1 nM, 5-HT release EC50 1937 nM, yielding a DA/5-HT selectivity ratio of 80 -- highly dopamine-selective with almost no serotonin activity. For comparison, unsubstituted amphetamine shows DA EC50 8.0 nM, NE EC50 7.2 nM, 5-HT EC50 1756 nM (DA/5-HT ratio 219). 4-FA sits at DA/5-HT ratio of only 18, reflecting the significant serotonergic activity responsible for its empathogenic effects and cardiovascular toxicity.
2-FA's profile likely falls somewhere between amphetamine and 3-FA in selectivity. The ortho fluorine's steric proximity to the amine nitrogen would alter binding kinetics differently than the meta or para positions, but the community consensus -- describing 2-FA as "clean" and "amphetamine-like" with no warmth or empathy -- points firmly toward a catecholamine-dominant profile.
In Vivo Behavioral Pharmacology: The Paradox
The Anchondo et al. (2025) study from the University of North Texas Health Science Center provides the only published behavioral data on 2-FA. The findings were counterintuitive:
Locomotor activity in mice: 2-FA produced peak locomotor effects of 5905-7758 counts -- matching methamphetamine's stimulant ceiling. Meanwhile, 2-FMA (the N-methylated, supposedly "stronger" analog) reached only 2200-3980 counts. The primary amine outperformed the secondary amine. This aligns with community reports: users consistently describe 2-FA as "speedier" and more stimulating at peak, while 2-FMA feels subtler and more controlled.
Drug discrimination in rats: All fluorinated analogs produced dose-dependent full substitution for methamphetamine, with ED50 values of 0.32-0.71 mg/kg. The conclusion was blunt: "These analogs may have a potential for abuse comparable to that of methamphetamine."
Metabolism and the 2-FMA Connection
2-FA metabolism is poorly characterized. It likely undergoes standard amphetamine metabolic pathways -- hydroxylation, deamination, and conjugation. Notably, 2-FA is itself a plausible metabolite of 2-FMA via N-demethylation, though it cannot serve as a definitive biomarker of 2-FMA use since 2-FA is independently available. CYP-mediated oxidative defluorination is theoretically possible but may be sterically hindered at the ortho position. Simmler et al. (2019) demonstrated that para-fluorination significantly increases serotonin transporter interaction (approximately 10-fold), while ortho-fluorination does not -- a finding with important implications for both pharmacology and metabolic toxicity.
Detection Methods
Standard Drug Screening
2-FA is not specifically detected by standard immunoassay-based drug panels (5-panel, 10-panel, etc.). The fluorine atom at the ortho position alters the molecular structure enough to reduce cross-reactivity with antibodies designed to detect unsubstituted amphetamine. However, some immunoassay kits may produce afalse positive for amphetamine due to structural similarity -- this is unpredictable and depends on the specific assay manufacturer and cutoff values used.
Detection Windows
- Urine: Approximately 2-4 days after last use (estimated from structural analogy to amphetamine; no specific pharmacokinetic data for 2-FA exists)
- Blood/serum: Approximately 12-48 hours
- Hair follicle: Up to 90 days, though specific 2-FA incorporation rates into hair have not been characterized
- Saliva: Estimated 1-2 days (no specific data available)
Confirmatory Analysis
Definitive identification of 2-FA requires GC-MS (gas chromatography-mass spectrometry) orLC-MS/MS (liquid chromatography-tandem mass spectrometry). These techniques can confirm the presence of 2-FA and distinguish it from other amphetamine-type substances.
Critical analytical challenge: Positional isomers (2-FA, 3-FA, and 4-FA) are extremely difficult to differentiate using standard chromatographic methods. They share the same molecular formula, similar fragmentation patterns, and often co-elute on standard columns. DrugsData.org has developed techniques to "reliably differentiate between 2- and 4-FA and 2- and 4-FMA" (available since September 2015), but many analytical laboratories lack this capability. Mohr et al. (2016) demonstrated indirect chiral separation of fluoroamphetamine isomers using specialized GC-MS and HPLC methods, but these are not routine procedures.
This analytical difficulty has direct harm reduction implications: a lab report confirming "fluoroamphetamine" without specifying the positional isomer does not tell you whether you have 2-FA or 4-FA (which has documented fatalities).
Reagent Testing
Reagent tests can provide preliminary identification but cannot distinguish positional isomers:
- Marquis: Faint orange-brown or no reaction
- Mecke: No reaction or minimal response
- Mandelin: Faint green-brown
- Simon's reagent: No reaction (negative for primary amines) -- this is useful for distinguishing 2-FA (primary amine) from 2-FMA (secondary amine, which produces a positive blue/purple reaction). If your sample tests positive with Simon's, it is not 2-FA.
Interactions
| Substance | Status | Note |
|---|---|---|
| Atropa belladonna | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Datura | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Diphenhydramine | Dangerous | Extreme cardiovascular strain from anticholinergic and stimulant effects combined |
| Harmala alkaloid | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| Peganum harmala | Dangerous | Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| DOx | Unsafe | — |
| PCP | Unsafe | — |
| 1,3-Butanediol | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 25E-NBOH | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-2 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 2C-T-21 | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Alcohol | Uncertain | — |
| Caffeine | Uncertain | — |
| Cannabis | Uncertain | — |
| Cocaine | Uncertain | — |
| GBL | Uncertain | — |
History
2-Fluoroamphetamine belongs to the wave of fluorinated amphetamine analogs that emerged in the novel psychoactive substance (NPS) market during the late 2000s and early 2010s. Unlike amphetamine itself -- which has a documented history stretching back to 1887 -- 2-FA's story is told through regulatory notifications and online forum discussions rather than academic papers or pharmaceutical development.
The first formal detection of 2-FA by European drug monitoring came in December 2008, when the EMCDDA recorded its initial notification. The compound entered a market exploring the full matrix of fluorinated amphetamine positional isomers: 2-FA, 3-FA, and 4-FA among the primary amines, plus their N-methylated counterparts 2-FMA, 3-FMA, and 4-FMA. Each carved out a distinct niche. 4-FA attracted users seeking an MDMA-like empathogenic experience. 3-FA drew recreational stimulant seekers with its dopaminergic character. 2-FA positioned itself as the functional option -- the "most amphetamine-like" of the series, chosen for productivity and focus.
The 4-FA catastrophe reshaped the fluoroamphetamine landscape. By the mid-2010s, 4-FA had become enormously popular in the Netherlands. Then the deaths accumulated -- cerebral hemorrhages, Takotsubo cardiomyopathy, subarachnoid hemorrhage, myocardial infarction, acute heart failure. The Netherlands banned 4-FA in 2017. The United States placed 4-FA in Schedule I effectiveFebruary 2026 (DEA Docket No. DEA-1180). These actions cast a shadow over all fluoroamphetamines, increasing scrutiny even for compounds that do not share 4-FA's serotonergic toxicity.
2-FA has remained niche -- used for functional stimulation and ADHD self-medication, but consistently overshadowed by 2-FMA's longer duration and cleaner side-effect profile. Academic study arrived late: Anchondo et al. (2025) published the first in vivo data on 2-FA, more than fifteen years after it entered the market.
Harm Reduction
Start Low, Go Oral
Begin with 10-15 mg taken orally. This is the threshold for meaningful effects and gives you a baseline for individual sensitivity before escalating. The oral route is strongly preferred over all alternatives -- not as a suggestion, but as a firm recommendation. Insufflation of 2-FA isextremely caustic. Multiple users report severe nasal burning, tissue damage, and nosebleeds lasting multiple days. The fluorine atom makes this compound significantly more corrosive to mucous membranes than standard amphetamine. The faster onset from nasal administration does not justify the tissue destruction.
The Ceiling Dose
Understand the ceiling effect before you dose. Beyond approximately 60 mg oral, 2-FA's desired effects (focus, mild euphoria, motivation) plateau while side effects (heart rate elevation, sweating, jitteriness, anxiety) continue to increase linearly. Pushing higher does not produce a better experience -- it produces the same cognitive effects with worse physical consequences. This is well-documented across Bluelight, Reddit, and Drugs-Forum. Respect the ceiling.
Test Your Substance -- This Is Not Optional
DrugsData has confirmed samples sold as 2-FA that actually contained 4-FA. This is not a theoretical risk. 4-Fluoroamphetamine is a significantly more dangerous compound with strong serotonergic activity and documented fatalities from cerebral hemorrhage, Takotsubo cardiomyopathy, and acute heart failure in the Netherlands. If you receive a powder labeled "2-FA" and it actually contains 4-FA, you are taking a fundamentally different drug with fundamentally different risks. Reagent test at minimum; GC-MS analysis through a drug checking service is ideal. Positional isomers are analytically challenging -- not all labs can distinguish 2-FA from 4-FA.
Frequency and Recovery
Tolerance develops rapidly -- effects can diminish to half within 3-7 days of daily use. Limit use to no more than twice per week, with full breaks of several days between sessions. Chronic stimulant use carries cardiovascular risks entirely uncharacterized for 2-FA.
Dangerous Combinations
- MAO inhibitors: Hypertensive crisis -- potentially fatal. Includes prescription MAOIs (phenelzine, tranylcypromine) and natural sources like ayahuasca and Syrian rue.
- Other stimulants (including high-dose caffeine): Compounding cardiovascular strain.
Sleep, Hydration, Nutrition
Do not dose after early afternoon. Stimulant-induced sleep deprivation is the primary catalyst for psychosis. Hydrate with electrolytes. Eat before dosing -- appetite suppression is significant. No clinical antidote exists; management is supportive care with benzodiazepines for agitation.
Toxicity & Safety
Cardiovascular Risks
All sympathomimetic stimulants elevate heart rate and blood pressure, and 2-FA is no exception. One Drugs-Forum user documented resting heart rate of 80 bpm and blood pressure of 160/100 during an 18-day trial at 10-50 mg doses. At higher doses, tachycardia, vasoconstriction, and palpitations become more pronounced. Chronic daily use of any amphetamine-type stimulant risks long-term cardiovascular damage; one Bluelight report describes daily 2-FMA use causing "cardio-toxic byproducts accumulating in fatty tissue, leading to severe heart arrhythmias requiring emergency surgery" -- a warning that transfers to 2-FA given their structural similarity.
Neurotoxicity: What We Know and What We Do Not
2-FA is believed not to produce the neurotoxic 4-hydroxyl metabolites associated with para-substituted amphetamines like 4-FA and PCA (para-chloroamphetamine). KnowDrugs notes that 2-FA "is believed not to produce certain neurotoxic metabolites associated with amphetamine." However, this is absence-of-evidence, not evidence of absence. CYP-mediated oxidative defluorination is theoretically possible, which could release fluoride and generate reactive metabolites. The ortho position may offer some steric protection, but this has not been systematically studied.
The critical distinction from 4-FA deserves emphasis: para-fluorination dramatically increases serotonin transporter interaction (Simmler 2019) and is linked to the cerebral hemorrhages and cardiovascular deaths documented in the Dutch 4-FA cohort. Ortho-fluorination (2-FA) does not produce this serotonergic enhancement. But this is the absence of one specific risk pathway -- it is not a clean bill of health. Community consensus places 2-FA's neurotoxicity profile as likely similar to d-amphetamine, not MDMA-level.
Hepatotoxicity
Para-halogenated amphetamines and methcathinones show greater mitochondrial toxicity than ortho-substituted compounds in SH-SY5Y cell assays (Luethi et al. 2019). 4-FMA has demonstrated in vitro hepatotoxicity mediated by CYP2E1, CYP2D6, and CYP3A4. The ortho position of 2-FA's fluorine may confer some metabolic protection compared to para-substituted analogs, but no direct hepatotoxicity data exists for 2-FA.
Addiction and the Ceiling as Partial Protection
The ceiling effect provides an unusual form of inherent protection: dose escalation beyond ~60 mg produces minimal additional reward while increasing side effects, discouraging runaway dose escalation. However, 2-FA's shorter duration may encourage more frequent redosing within a session, partially offsetting this protection.
The Bottom Line
No formal toxicological data exists for 2-FA. No LD50 has been established. No chronic exposure studies have been conducted. No standalone fatality has been attributed to 2-FA. The absence of reported deaths is reassuring but reflects limited use, not demonstrated safety.
Addiction Potential
2-FA carries **moderate addiction potential with high abuse liability**. KnowDrugs rates it as "moderately addictive with a high potential for abuse," and the Anchondo et al. (2025) drug discrimination data -- full substitution for methamphetamine in trained rats -- supports this assessment. The ceiling effect provides partial inherent protection. Unlike cocaine or methamphetamine, 2-FA's euphoric effects plateau around 60 mg while side effects continue climbing. One Bluelight user described the redosing urge as coming "not exactly because the reward was so big but it seemed to be right around the corner but never really came." However, 2-FA's shorter duration (3-6 hours versus 2-FMA's 6-10+) may encourage more frequent redosing within a session, partially offsetting this protection. Tolerance develops rapidly -- effects can reduce to half within 3-7 days of regular use. Cross-tolerance exists with all dopaminergic stimulants. Psychological dependence develops through reinforcement of the productivity-reward cycle. Withdrawal consists of fatigue, increased appetite, anhedonia, and mild depression.
Overdose Information
Stimulant overdose is a medical emergency. 2-FA's shorter duration compared to compounds like 2-FMA or methamphetamine means that acute symptoms may resolve faster, but this does not reduce the need for immediate medical attention -- cardiovascular collapse, seizures, and hyperthermia can kill within the acute window regardless of the drug's half-life.
Warning Signs
Seek emergency help immediately for any of the following:
- Extremely rapid or irregular heartbeat -- palpitations, chest pounding, skipped beats
- Severe chest pain or pressure
- Hyperthermia (high body temperature) -- hot skin, confusion, disorientation
- Seizures
- Severe agitation, paranoia, or psychosis -- loss of contact with reality
- Intense headache with vision changes (possible hypertensive emergency)
What To Do
Call emergency services immediately. Good Samaritan laws in most US states protect callers from prosecution for drug-related emergencies. While waiting for help:
- Cool the person down. Move them to a cool environment. Apply cold water or ice packs to the neck, armpits, and groin -- major blood vessel sites for heat exchange. Hyperthermia dramatically worsens all stimulant toxicities.
- Keep them calm. Reduce sensory stimulation -- dim lights, lower noise, speak in a calm voice. Avoid physical restraint, which worsens hyperthermia and cardiac strain through struggling.
- If they are seizing, protect their head and clear surrounding hazards. Do not put anything in their mouth.
- If unconscious and not breathing, begin CPR.
- Offer water if conscious and able to swallow.
Hospital Treatment
Emergency departments use benzodiazepines as first-line therapy for agitation, seizures, and hypertension. Active cooling addresses hyperthermia. Beta-blockers are generally avoided due to risk of unopposed alpha-adrenergic vasoconstriction.No specific antidote exists -- all management is supportive. 2-FA's shorter duration (3-6 hours) means symptoms may improve sooner than with longer-acting stimulants, but this should never delay seeking medical care.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Extreme cardiovascular strain from anticholinergic and stimulant effects combined
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Risk of hypertensive crisis and serotonin syndrome; potentially fatal combination
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 10 days |
Cross-tolerances
Legal Status
2-Fluoroamphetamine occupies a legal grey zone in most jurisdictions -- not explicitly named in controlled substance schedules but potentially captured by analog laws and generic NPS legislation. The legal landscape varies dramatically by country, and in some cases 2-FA receives notably different legal treatment than its close relative 2-FMA.
United States
2-FA is not explicitly scheduled under the federal Controlled Substances Act. However, it is potentially prosecutable under theFederal Analogue Act (21 U.S.C. 813) when intended for human consumption, treated as a Schedule I or II analog of amphetamine. Several states have moved independently:Nevada scheduled 2-FA in 2023,Illinois lists it as Schedule I, andWest Virginia classifies it as Schedule I.
The placement of 4-FA into federal Schedule I effective February 2026 increases scrutiny on all fluoroamphetamine isomers and may accelerate future scheduling actions for 2-FA.
Germany: A Key Legal Distinction
2-FA and 2-FMA receive fundamentally different treatment in Germany -- an important distinction:
- 2-FA falls under theNpSG (Neue-psychoaktive-Stoffe-Gesetz) since November 2016. The NpSG uses generic group-based definitions.Production and sale are banned, but personal possession is NOT a criminal offense.
- 2-FMA is individually listed underAnlage I BtMG (Narcotics Act, Schedule I) since December 2014. Under the BtMG,possession itself is criminal, punishable by fine or up to five years imprisonment.
The same person possessing 2-FA versus 2-FMA faces completely different legal consequences despite the compounds differing by a single methyl group.
United Kingdom
Controlled as Class A under the Misuse of Drugs Act 1971, falling under the 1977 amendment covering phenethylamine derivatives with ring substitutions. ThePsychoactive Substances Act 2016 provides additional blanket coverage of NPS. Penalties for Class A possession are up to 7 years imprisonment.
Other Jurisdictions
- China: Controlled since October 1, 2015 as part of a batch of 116 NPS listings including 23 phenethylamines.
- Canada: Likely Schedule I as an amphetamine analog (2-FMA is explicitly Schedule I since 1996).
- Switzerland: Status under BetmVV-EDI (Narcotics Law Directory) remains unclear; Switzerland uses a hybrid system with individual listings and structure-analogue definitions.
- Netherlands: 4-FA banned since 2017; 2-FA likely covered under amphetamine analogue provisions.
Experience Reports (2)
Tips (4)
Do not take 2-FA in the afternoon or evening if you want to sleep that night. Most stimulants have long half-lives and even if you feel you can sleep, the quality will be significantly impaired.
Test 2-FA with appropriate reagent kits and fentanyl test strips. Stimulant supplies have increasingly been found contaminated with fentanyl, which has caused a surge in overdose deaths among stimulant users.
Start low with 2-FA and wait for full onset before redosing. Stimulant redosing extends duration and side effects more than it extends euphoria, while adding cardiovascular strain. Set a firm limit before you start.
Monitor your heart rate and blood pressure when using 2-FA. Sustained elevated cardiovascular stress causes cumulative damage. If you experience chest pain, irregular heartbeat, or numbness in extremities, seek medical attention.
See Also
References (3)
- Amphetamine: new content for an old topic — Heal et al. Neuropsychopharmacology Reviews (2013)paper
- 2-FA - TripSit Factsheet
TripSit factsheet for 2-FA
tripsit - 2-FA - Wikipedia
Wikipedia article on 2-FA
wikipedia